SCHEMBL1017293

SCHEMBL1017293

Cc1cc2c(NC3CCC3)nc(Cl)nc2[nH]1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EHMT2 Q96KQ7 1/20 0.41
KMT2A Q03164 1/20 0.40
KDM4E B2RXH2 3/20 0.40
LMNA P02545 2/20 0.40
ALDH1A1 P00352 1/20 0.40
MAPT P10636 1/20 0.40
SMN1; SMN2 Q16637 2/20 0.39
POLB P06746 1/20 0.39
GAA P10253 1/20 0.39
PDE10A Q9Y233 1/20 0.38
CHRM4 P08173 3/20 0.37
CYP1A2 P05177 1/20 0.37
CYP2D6 P10635 1/20 0.37
HSD17B10 Q99714 1/20 0.37
PDE4A P27815 1/20 0.37
PLK4 O00444 1/20 0.36
PAK4 O96013 1/20 0.36
RAB9A P51151 1/20 0.36
AXL P30530 1/20 0.36
CCR4 P51679 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24312397 0.97 KMT2A (0.43) EHMT2KMT2AKDM4ELMNAALDH1A1
SCHEMBL22606155 0.94 EHMT2 (0.42) EHMT2KMT2AKDM4ELMNAALDH1A1
SCHEMBL22606446 0.76 TLR7 (0.39) KMT2ALMNAALDH1A1GAACHRM4
SCHEMBL22587446 0.76 GAA (0.39) ALDH1A1POLBGAAPDE10APLK4
SCHEMBL29426252 0.76 GAA (0.39) ALDH1A1POLBGAAPDE10APLK4
SCHEMBL22587506 0.75 ACP1 (0.62) KMT2AKDM4ELMNAALDH1A1CYP1A2
SCHEMBL22587463 0.75 GBA1 (0.60) KMT2AKDM4ELMNAALDH1A1CYP1A2
SCHEMBL22587451 0.74 ACP1 (0.63) KMT2AKDM4ELMNAALDH1A1SMN1; SMN2
SCHEMBL1018595 0.74 HPGDS (0.56) KMT2AKDM4EHSD17B10PAK4ADORA3
SCHEMBL3536147 0.72 EGFR (0.58) KDM4ELMNAALDH1A1SMN1; SMN2HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2271631-B1 INHIBITORS OF PROTEIN KINASES PORTOLA PHARM INC (US) 2018-07-04 EP disclosed
US-9139581-B2 Inhibitors of protein kinases PORTOLA PHARMACEUTICALS, INC. (US) 2015-09-22 US disclosed
CN-103224497-A Inhibitors of protein kinases PORTOLA PHARM INC 2013-07-31 CN disclosed
US-20130029944-A1 INHIBITORS OF PROTEIN KINASES PORTOLA PHARMACEUTICALS, INC. (US) 2013-01-31 US disclosed
US-8258144-B2 Inhibitors of protein kinases PORTOLA PHARMACEUTICALS, INC. (US) 2012-09-04 US disclosed
EP-2271631-A2 INHIBITORS OF PROTEIN KINASES Portola Pharmaceuticals, Inc. (US) 2011-01-12 EP disclosed
US-20090298823-A1 Inhibitors of protein kinases PORTOLA PHARMACEUTICALS, INC. (US) 2009-12-03 US disclosed
WO-2009131687-A2 INHIBITORS OF PROTEIN KINASES PORTOLA PHARMACEUTICALS, INC. (US) 2009-10-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130029944-A1 INHIBITORS OF PROTEIN KINASES SYK, BTK, JAK2 EHMT2 4186/4885KMT2A 1671/4885KDM4E 1124/4885
US-20090298823-A1 Inhibitors of protein kinases SYK, BTK, JAK2 EHMT2 4186/4885KMT2A 1671/4885KDM4E 1124/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.